LEDIPASVIR AND SOFOSBUVIR ARE SUBSTRATES OF DRUG TRANSPORTERS P-GP AND BCRP WHILE GS-331007 IS NOT. P-GP INDUCERS (E.G., RIFAMPIN OR ST. JOHN'S WORT) MAY DECREASE LEDIPASVIR AND SOFOSBUVIR PLASMA CONCENTRATIONS, LEADING TO REDUCED THERAPEUTIC EFFECT OF HARVONI.
COADMINISTRATION WITH DRUGS THAT INHIBIT P-GP AND/OR BCRP MAY INCREASE LEDIPASVIR AND SOFOSBUVIR PLASMA CONCENTRATIONS.
NO DETECTABLE METABOLISM OF LEDIPASVIR BY CYP ENZYMES HAS BEEN OBSERVED.